RadNet (RDNT): The FDA Clearance Is Just the Tip — The Core Business Is Growing 20%+ While Trading at a Traditional Imaging Multiple

RadNet's subsidiary DeepHealth received FDA clearance for its AI-powered breast ultrasound solution on July 30, 2026. The market read the headline and shrugged.

The story isn't the FDA clearance. The FDA clearance is just the latest in a pipeline of regulatory approvals for a company whose core imaging business is growing 20%+ on revenue and 30%+ on EBITDA, while the AI division more than doubled its annual recurring revenue in twelve months. The market is pricing RadNet like a slow-growth imaging center operator with debt. The math says otherwise.

1. The core imaging business is accelerating, not coasting.

Total revenue jumped 22.1% to $575.6 million in Q1 2026. Adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, a proxy for operating cash generation — surged 36.3% to $63.3 million. These numbers came despite an estimated $13 million revenue hit from severe winter weather in the Northeast. After the weather cleared in March, the business rebounded hard enough that RadNet raised its full-year guidance.

Same-center advanced imaging volumes — MRI, CT, and PET/CT, excluding growth from acquisitions — grew 8.2%. MRI alone was up 10% at existing centers. The procedural mix is shifting toward higher-margin advanced imaging, which climbed from 26.9% of total volume to 29.3% year over year. That's a 235-basis-point shift in a single quarter.

Revised 2026 guidance calls for Imaging Center revenue of $2.355–$2.405 billion (17–19% growth) and adjusted EBITDA of $340–$353 million (18–22% growth). Free cash flow is guided to $112–$122 million, up 29–41%. This isn't a company on the ropes.

2. The AI division is scaling from a rounding error into a real business.

Digital Health revenue grew 51.5% to $29.1 million in Q1 2026. More importantly, annual recurring revenue — the committed revenue base from subscription-style contracts — more than doubled from $49.8 million to $96.9 million in twelve months. Full-year 2026 Digital Health revenue is guided at $135–$145 million, representing 46–56% growth.

The new breast ultrasound AI — DeepHealth's SMART-B device — adds to a growing portfolio. It localizes breast lesions with over 98% accuracy, improves cancer detection sensitivity by 8%, and cuts radiologist interpretation time by 37%. It's commercially available immediately. RadNet estimated more than 700,000 breast ultrasound studies annually across its own network are eligible, with an existing Category III CPT reimbursement code available.

The breast ultrasound clearance matters less as a standalone revenue driver than as proof that DeepHealth is executing across modalities — mammography, prostate MRI, now ultrasound. Management guided for a minimum of four FDA clearances in 2026. By year-end, over 70% of RadNet's own imaging studies will run through clinical AI.

Third-party sales are the longer-term optionality. DeepHealth signed over $16 million in total contract value with external customers in Q1 alone. Management expects internal revenue share to decline from 45% to 33%, meaning two-thirds of Digital Health revenue will come from hospitals and imaging centers outside RadNet by 2026.

3. The valuation tells the real story.

RadNet trades at a market cap of approximately $5.7 billion with an enterprise value of roughly $7.2 billion, reflecting about $1.85 billion in debt. Combined 2026 EBITDA guidance — Imaging Centers plus Digital Health, before non-capitalized R&D — lands near $350–365 million at the mid-point.

That puts the stock at roughly 20 times 2026 EV/EBITDA. For a traditional imaging center operator, that would be expensive. But RadNet isn't a traditional imaging center operator anymore. The core business is growing EBITDA at 18–22% while the AI segment is growing revenue at 50%+. Management also guided for approximately $117 million in free cash flow — enough to service debt while keeping a $455 million cash balance on the books. Net debt to adjusted EBITDA sits slightly below 2.0x, manageable for a company of this cash-generating scale.

Eight analysts cover the stock with a consensus "Strong Buy" rating and an average price target of $89.75 — about 24% above the current price of $72. The analyst view isn't the thesis, but it does reflect the gap between current pricing and the trajectory of the numbers.

4. The disconnect.

The market has partially rewarded RadNet — the stock is up roughly 43% over the past year — but the re-rating hasn't gone all the way. Much of the remaining optionality sits in the Digital Health segment, which is still guided for only modest EBITDA before non-capitalized R&D ($10–12 million). The $17–19 million in non-capitalized R&D spending for DeepHealth Cloud OS and generative AI is a headwind on paper but an investment in a platform that could scale far beyond RadNet's own imaging network.

When Digital Health starts generating meaningful standalone profitability — management's ARR targets suggest it could approach $140 million by year-end — the market will need to reassess whether RadNet is an imaging company with an AI division or an AI company with an imaging cash machine funding its growth.

The risk

Debt is real. $1.85 billion in total debt with $45–$50 million in annual cash interest expense. GAAP losses persist — Q1 2026 showed a net loss of $33.5 million before adjustments. Integration risk from recent acquisitions (Gleamer SAS, iCAD, See-Mode, CIMAR) is material. A broad economic slowdown could dampen elective imaging volumes.

The break condition

The gap closes if Q2 and Q3 results confirm the accelerated trajectory — same-center volume growth holds above 8%, Digital Health ARR continues doubling, and the breast ultrasound solution converts to measurable third-party revenue. Each quarterly report that beats the raised guidance narrows the distance between the current multiple and what a 20%+ EBITDA growth company actually commands.

The FDA clearance was a headline. The EBITDA growth is the thesis.